How does a SAFE affect my startup's 409A fair market value?

A SAFE can affect your 409A in two ways: it brings cash into the company, and it creates a contractual claim that may convert into equity later. Both belong in the analysis. Neither means the SAFE's valuation cap becomes your common-stock fair market value.

The cap is a conversion term, not necessarily a negotiated statement of what the company is worth today. The valuation has to consider the full agreement: amount invested, cap, discount, most-favored-nation terms, conversion mechanics, seniority or priority, and the likelihood and timing of the next financing.

Scale matters. A small SAFE may add runway without materially changing the conclusion. A large SAFE round can change the company's cash position, reduce near-term financing risk, and provide meaningful market evidence. Different terms across several SAFEs can also change the future dilution and the economic rights sitting ahead of common stock.

The appraiser should model the instruments consistently with the company's capital structure and the valuation method. That may mean incorporating the financing into scenario analysis or the allocation of equity value rather than treating every SAFE like priced preferred stock.

And common stock is still the target. Even if the SAFE implies useful evidence about enterprise or equity value, employee common shares remain illiquid and sit behind contractual investor economics. The 409A conclusion comes after those differences are analyzed, because a 409A measures common-stock FMV, not the headline value of a financing instrument.

For the financing-timing question, read whether a SAFE round triggers a new 409A. For the broader analytical toolkit, see the 409A methodology explainer and the process section of the founder's guide.